Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Table 5 Number (%) of participants with dermatological endpoints and treatment differences

Adverse event category	Number (%)			Treatment difference (95% CI)
Adverse event category	12 mg (N = 652)	40 mg (N = 652)	Placebo (N = 653)	12 mg vs. placebo	40 mg vs. placebo
Hypopigmentation composite endpoint^a	16 (2.5)	16 (2.5)	14 (2.1)	0.31 (− 1.39, 2.04)	0.31 (− 1.39, 2.04)
Hypopigmentation event of clinical interest	10 (1.5)	9 (1.4)	11 (1.7)	− 0.15 (− 1.64, 1.32)	− 0.3 (− 1.77, 1.12)
Rash event of clinical interest	30 (4.6)	28 (4.3)	8 (1.2)	3.38 (1.63, 5.39)	3.07 (1.36, 5.04)
Severe rash^b	0 (0.0)	0 (0.0)	0 (0.0)	0	0

^aComprised of the following terms: skin hypopigmentation, skin depigmentation, vitiligo, leukoderma, hypopigmentation of the eyelid, and idiopathic guttate hypomelanosis
^bStevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms

ISSN: 1758-9193